Chemotherapy of trypanosomiasis: the potentiation of antimonial compounds by difluoromethylornithine (DFMO).
The currently available anti-leishmanial antimonial drugs, together with other antimony compounds were individually tested, in combination with difluoromethylornithine (DFMO), against experimental murine trypanosomiasis with central nervous system involvement. Satisfactory cure rates could be achieved using a combination treatment of DFMO with most of these anti-leishmanial drugs, but in general, only when they were administered at least twice daily. Of the compounds tested, the most effective was antimony dimercaptosuccinate (Astiban).
Jennings
F W
FW
Department of Veterinary Parasitology, University of Glasgow, England.
D000818:Animals; D000965:Antimony / Q000494:pharmacology / Q000627:therapeutic use*; D000967:Antimony Sodium Gluconate / Q000494:pharmacology / Q000627:therapeutic use; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D000518:Eflornithine / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D008536:Meglumine / Q000494:pharmacology / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D051379:Mice; D009942:Organometallic Compounds / Q000494:pharmacology / Q000627:therapeutic use; D004113:Succimer / Q000494:pharmacology / Q000627:therapeutic use; D013644:Tartrates / Q000494:pharmacology / Q000627:therapeutic use; D014344:Trypanocidal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D014346:Trypanosoma brucei brucei / Q000187:drug effects*; D014353:Trypanosomiasis, African / Q000188:drug therapy*
D009942:Organometallic Compounds; D013644:Tartrates; D014344:Trypanocidal Agents; C026019:antimony sodium tartrate; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000965:Antimony; C004443:stibocaptate; D004113:Succimer; C004409:anthiolimine; D000967:Antimony Sodium Gluconate; D000518:Eflornithine